drugset / Trial / NCT05480592

A Study of HS-10380 in Chinese Participants

NCT05480592

Phase 1 Unknown 76 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10380 in Chinese healthy subjects.

Timeline

Start
2022-08-01
Primary completion
2023-06-30
Completion
2023-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-10380 Unknown Oral

Indications